Pacific Biosciences of California, Inc.
Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.17% over 10 days); RSI 29 — oversold; weak 1-year return of -11.7%; 3-month momentum negative (-12.8%). Currently 50.2% off its 52-week high. Score: -7/7.
PACB is trading below its 200-day MA ($1.71) — a key warning sign the longer-term trend is under pressure. An RSI of 29.2 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -11.7% compares to +16.5% for SPY (trailed the market by 28.2%). The current 50.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.